ME02277B - Postupak za prečišćavanje rekombinantnog fsh - Google Patents
Postupak za prečišćavanje rekombinantnog fshInfo
- Publication number
- ME02277B ME02277B MEP-2015-172A MEP17215A ME02277B ME 02277 B ME02277 B ME 02277B ME P17215 A MEP17215 A ME P17215A ME 02277 B ME02277 B ME 02277B
- Authority
- ME
- Montenegro
- Prior art keywords
- insulin secretagogue
- combination
- glimepiride
- glipizide
- use according
- Prior art date
Links
- 229940122199 Insulin secretagogue Drugs 0.000 claims 10
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims 6
- 229960004346 glimepiride Drugs 0.000 claims 6
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical group C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 6
- 229960001381 glipizide Drugs 0.000 claims 6
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- WHSOLWOTCHFFBK-ZQGJOIPISA-N Luseogliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=C(OC)C=C1C WHSOLWOTCHFFBK-ZQGJOIPISA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960004580 glibenclamide Drugs 0.000 claims 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (12)
1. Farmaceutski preparat naznačen time što sadrži kombinaciju(A) (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-D-glucitola ili njegove farmaceutski prihvatljive soli ili hidrata takvog jedinjenja ili soli; i(B) sekretagoga insulina.
2. Farmaceutski preparat prema patentnom zahtevu 1, naznačen time što je navedeni sekretagog insulina glipizid, glibenklamid ili glimepirid.
3. Farmaceutski preparat prema patentnom zahtevu 2, naznačen time što je navedeni sekretagog insulina glipizid ili glimepirid.
4. Farmaceutski preparat prema patentnom zahtevu 2, naznačen time što je navedeni sekretagog insulina glipizid.
5. Farmaceutski preparat prema patentnom zahtevu 2, naznačen time što je navedeni sekretagog insulina glimepirid.
6. Kombinacija: (A)(1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-D-glucitola ili njegove farmaceutski prihvatljive soli ili hidrata takvog jedinjenja ili soli; i (B) sekretagoga insulina za upotrebu u postupku prevencije ili lečenja dijabetesa melitusa, bolesti koje se dovode u vezu sa dijabetesom melitusom ili komplikacija dijabetesa melitusa, gde se (A) i (B) primenjuju kod pacijenta kome je to potrebno, bilo istovremeno ili odvojeno.
7. Kombinacija za upotrebu prema patentnom zahtevu 6, naznačena time što je navedeni sekretagog insulina glipizid, glibenklamid i glimepirid.
8. Kombinacija za upotrebu prema patentnom zahtevu 7, naznačena time što je navedeni sekretagog insulina glipizid ili glimepirid.
9. Kombinacija za upotrebu prema patentnom zahtevu 7, naznačena time što je navedeni sekretagog insulina glipizid.
10. Kombinacija za upotrebu prema patentnom zahtevu 7, naznačena time što je navedeni sekretagog insulina glimepirid.
11. Kombinacija za upotrebu prema bilo kom od patentnih zahteva 6 do 10, naznačena time što je dijabetes melitus dijabetes tipa 2.
12. Kombinacija za upotrebu prema bilo kom od patentnih zahteva 6 do 11, naznačena time što je komplikacija dijabetesa melitusa dijabetska retinopatija, dijabetska nefropatija, dijabetska neuropatija, cerebrovaskularni poremećaj, ishemijska bolest srca ili bolest perifernih arterija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09157133 | 2009-04-01 | ||
| PCT/EP2010/002111 WO2010115586A2 (en) | 2009-04-01 | 2010-04-01 | Method for purifying recombinant fsh |
| EP10713424.9A EP2414380B1 (en) | 2009-04-01 | 2010-04-01 | Method for purifying recombinant fsh |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02277B true ME02277B (me) | 2016-02-20 |
Family
ID=42153744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-172A ME02277B (me) | 2009-04-01 | 2010-04-01 | Postupak za prečišćavanje rekombinantnog fsh |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9096683B2 (me) |
| EP (1) | EP2414380B1 (me) |
| JP (2) | JP5845170B2 (me) |
| KR (1) | KR101761168B1 (me) |
| CN (1) | CN102448979B (me) |
| AU (1) | AU2010234028B2 (me) |
| BR (1) | BRPI1012647B1 (me) |
| CA (1) | CA2755927A1 (me) |
| CY (1) | CY1116963T1 (me) |
| DK (1) | DK2414380T3 (me) |
| EA (1) | EA028065B1 (me) |
| ES (1) | ES2552055T3 (me) |
| HR (1) | HRP20151086T1 (me) |
| HU (1) | HUE025959T2 (me) |
| IL (1) | IL215234A (me) |
| ME (1) | ME02277B (me) |
| MX (1) | MX2011010480A (me) |
| NZ (1) | NZ595661A (me) |
| PL (1) | PL2414380T3 (me) |
| PT (1) | PT2414380E (me) |
| RS (1) | RS54318B1 (me) |
| SI (1) | SI2414380T1 (me) |
| SM (1) | SMT201500276B (me) |
| UA (1) | UA106369C2 (me) |
| WO (1) | WO2010115586A2 (me) |
| ZA (1) | ZA201106800B (me) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5845170B2 (ja) * | 2009-04-01 | 2016-01-20 | ラティオファーム ゲーエムベーハー | 組換えｆｓｈを精製する方法 |
| CN103570820B (zh) * | 2012-08-06 | 2015-11-18 | 齐鲁制药有限公司 | 一种重组人促卵泡激素的纯化方法 |
| KR101516054B1 (ko) * | 2012-11-21 | 2015-05-06 | 씨제이헬스케어 주식회사 | 신규한 지속형 인간 성장호르몬 단량체를 제조하는 방법 |
| CN103059125B (zh) * | 2012-12-27 | 2015-08-12 | 浙江海正药业股份有限公司 | 重组人促卵泡激素的纯化方法 |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| CN103539860B (zh) * | 2013-11-01 | 2014-12-03 | 广州优联康医药科技有限公司 | 一种长效重组人促卵泡激素融合蛋白 |
| CN103539861B (zh) * | 2013-11-01 | 2015-02-18 | 广州联康生物科技有限公司 | 长效重组人促卵泡激素融合蛋白 |
| CA2945591A1 (en) * | 2014-04-18 | 2015-10-22 | Cadila Healthcare Limited | Novel purification process of gonadotropin |
| CN104479005B (zh) * | 2014-09-05 | 2017-10-31 | 上海丽珠制药有限公司 | 一种促性腺激素纯化的方法 |
| CN105461799A (zh) * | 2015-12-31 | 2016-04-06 | 哈药集团技术中心 | 一种重组人促卵泡生成素的纯化方法 |
| CN106117342B (zh) * | 2016-07-07 | 2020-01-03 | 江西浩然生物医药有限公司 | 一种高纯度尿促卵泡素的制备方法 |
| RU2694598C1 (ru) * | 2018-08-07 | 2019-07-16 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Клеточная линия huFSHKKc6 - продуцент рекомбинантного человеческого фолликулостимулирующего гормона (ФСГ) и способ получения ФСГ с использованием данной линии |
| KR102752765B1 (ko) * | 2019-12-26 | 2025-01-14 | 주식회사 엘지화학 | 여포 자극 호르몬의 정제 방법 |
| KR102283871B1 (ko) * | 2021-03-02 | 2021-08-02 | 한국원자력연구원 | 크로마토그래피를 이용한 무담체 홀뮴-166의 분리 방법, 분리 장치 및 이에 의하여 분리된 무담체 홀뮴-166 |
| CN113372433B (zh) * | 2021-03-12 | 2022-10-11 | 上海景泽生物技术有限公司 | 纯化fsh方法 |
| CN114591414A (zh) * | 2022-03-24 | 2022-06-07 | 江西浩然生物制药有限公司 | 一种人绒毛膜促性腺激素的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923805A (en) | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
| US6455282B1 (en) * | 1983-11-02 | 2002-09-24 | Genzyme Corporation | Cells, vectors and methods for producing biologically active TSH |
| US4840896A (en) | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
| IT1206302B (it) | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
| CA2018676C (en) | 1989-06-20 | 2003-05-06 | Christie A. Kelton | Novel heteropolymeric protein production methods |
| US5021160A (en) * | 1990-01-09 | 1991-06-04 | Gelman Sciences, Inc. | Strongly acidic microporous membranes for cation exchange |
| DE4440587A1 (de) | 1994-11-14 | 1996-05-15 | Fliether Karl Gmbh & Co | Basquill-Schloß |
| US6261823B1 (en) * | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| AU747179B2 (en) | 1997-06-25 | 2002-05-09 | Merck Serono Sa | Disulfide cross-linked glycoprotein hormone analogs, their preparation and use |
| US6414123B1 (en) * | 1997-10-21 | 2002-07-02 | Vitro Diagnostics, Inc. | Method for purifying FSH |
| US5990288A (en) * | 1997-10-21 | 1999-11-23 | Vitro Diagnostics, Inc. | Method for purifying FSH |
| ATE358139T1 (de) | 1999-04-16 | 2007-04-15 | Inst Massone S A | Verfahren zur herstelllung von gonadotropin- zusammensetzungen |
| WO2001058493A1 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | Conjugates of follicle stimulating hormones |
| US7157277B2 (en) * | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| AU2003240832A1 (en) | 2002-05-31 | 2003-12-19 | E.I. Du Pont De Nemours And Company | Copolymers having tunable energy levels and color of emission |
| WO2004087213A1 (en) | 2003-04-02 | 2004-10-14 | Ares Trading S.A. | Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
| ATE446314T1 (de) * | 2003-12-22 | 2009-11-15 | Ares Trading Sa | Methode zur reinigung von fsh |
| EP1809663B1 (en) | 2004-11-09 | 2008-09-17 | Ares Trading S.A. | Method for purifying fsh |
| TW200728316A (en) * | 2005-12-09 | 2007-08-01 | Ares Trading Sa | Method for purifying FSH or a FSH mutant |
| JP5199112B2 (ja) * | 2005-12-09 | 2013-05-15 | アレス トレーディング ソシエテ アノニム | Ｆｓｈ又はｆｓｈ変異体を精製するための方法 |
| CN101720332B (zh) | 2007-06-28 | 2014-08-13 | 拉蒂奥法姆有限责任公司 | 生产促卵泡激素的细胞克隆 |
| CL2008002054A1 (es) * | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico. |
| JP5845170B2 (ja) * | 2009-04-01 | 2016-01-20 | ラティオファーム ゲーエムベーハー | 組換えｆｓｈを精製する方法 |
-
2010
- 2010-04-01 JP JP2012502514A patent/JP5845170B2/ja not_active Expired - Fee Related
- 2010-04-01 BR BRPI1012647-3A patent/BRPI1012647B1/pt not_active IP Right Cessation
- 2010-04-01 EP EP10713424.9A patent/EP2414380B1/en active Active
- 2010-04-01 PT PT107134249T patent/PT2414380E/pt unknown
- 2010-04-01 MX MX2011010480A patent/MX2011010480A/es unknown
- 2010-04-01 RS RS20150682A patent/RS54318B1/sr unknown
- 2010-04-01 KR KR1020117025974A patent/KR101761168B1/ko not_active Expired - Fee Related
- 2010-04-01 US US13/262,622 patent/US9096683B2/en not_active Expired - Fee Related
- 2010-04-01 NZ NZ595661A patent/NZ595661A/xx not_active IP Right Cessation
- 2010-04-01 PL PL10713424T patent/PL2414380T3/pl unknown
- 2010-04-01 WO PCT/EP2010/002111 patent/WO2010115586A2/en not_active Ceased
- 2010-04-01 HU HUE10713424A patent/HUE025959T2/en unknown
- 2010-04-01 UA UAA201112796A patent/UA106369C2/ru unknown
- 2010-04-01 ES ES10713424.9T patent/ES2552055T3/es active Active
- 2010-04-01 AU AU2010234028A patent/AU2010234028B2/en not_active Ceased
- 2010-04-01 DK DK10713424.9T patent/DK2414380T3/en active
- 2010-04-01 CA CA2755927A patent/CA2755927A1/en not_active Abandoned
- 2010-04-01 ME MEP-2015-172A patent/ME02277B/me unknown
- 2010-04-01 CN CN201080022681.1A patent/CN102448979B/zh active Active
- 2010-04-01 HR HRP20151086TT patent/HRP20151086T1/hr unknown
- 2010-04-01 SI SI201031050T patent/SI2414380T1/sl unknown
- 2010-04-01 EA EA201171199A patent/EA028065B1/ru not_active IP Right Cessation
-
2011
- 2011-09-15 ZA ZA2011/06800A patent/ZA201106800B/en unknown
- 2011-09-19 IL IL215234A patent/IL215234A/en active IP Right Grant
-
2015
- 2015-06-15 US US14/739,935 patent/US20150353599A1/en not_active Abandoned
- 2015-09-09 JP JP2015177674A patent/JP6231056B2/ja not_active Expired - Fee Related
- 2015-10-30 CY CY20151100971T patent/CY1116963T1/el unknown
- 2015-11-04 SM SM201500276T patent/SMT201500276B/it unknown
-
2016
- 2016-07-01 US US15/200,714 patent/US20160304575A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20141080T1 (hr) | Farmaceutski pripravci s (1s) -1,5-anhidro-1 [5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom inzulina | |
| HRP20231586T1 (hr) | Agonisti receptora glukagonu sličnog peptida 1 | |
| ME01546B (me) | Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2 | |
| JP2014511863A5 (me) | ||
| WO2006105501A3 (en) | Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin | |
| FI3716979T3 (fi) | 4-pyrimidiinisulfamidijohdannaisen ja SGLT-2-inhibiittorin yhdistelmä endoteliiniin liittyvien sairauksien hoitamiseksi | |
| BRPI0818687A2 (pt) | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. | |
| JP2012236849A5 (me) | ||
| FI2396005T3 (fi) | Sglt2:n estäjä verensokeritasapainon parantamiseksi | |
| JP2012511586A5 (me) | ||
| JP2017538705A5 (me) | ||
| WO2016060517A3 (ko) | 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제 | |
| CA2896308C (en) | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders | |
| JP2018503644A5 (me) | ||
| JP2018509419A5 (me) | ||
| JP2008545715A5 (me) | ||
| JP2013166781A5 (me) | ||
| Erlich et al. | Diabetes update: new drugs to manage type 2 diabetes | |
| WO2011122815A3 (en) | Novel quinoxaline derivatives | |
| RU2018139578A (ru) | Способ лечения гипергликемии | |
| Chung et al. | Torsade de pointes in liver transplantation recipient after induction of general anesthesia: a case report | |
| Kalra | Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations | |
| Agarwal et al. | Study of optimal basal insulin glargine dose requirement in Indian population as an add on therapy to oral hypoglycaemic agents to achieve target fasting blood glucose levels | |
| Zakhidova | Correction of anemic syndrome in patients with chronic heart failure with intravenous iron-containing complex | |
| TH2101002485A (th) | องค์ประกอบทางเภสัชกรรมสำหรับรักษาโรคเบาหวานชนิดที่ 2 |